Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO
LEXARIA BIOSCIENCE CORP. LXRP
Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO
August 14, 2017
In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line almost as much as they would raise revenues. Lexaria will be employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit. The company expects to have its first major agreement wrapped up by the end of the year.
News 
Market Data 
Discover 
